Our New Website Is Here!
As part of our merger with St. Paul Research, we’ve created a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through our analysts’ combined insight, expertise, and perspective. Go to my.stpaulresearch.com to access our new site.

“Moon Landing” Vaccine Technology (With a Hitch)

A reader writes about the outcome of the election, saying: “No need to hurry while there ARE claims of widespread voter fraud.

“And electronic voting machines in every precinct aren’t the answer. Automating a corrupt count only makes it easier and faster to steal an election.

“Resistance to cleaning up election rolls and voter ID needs to be overcome. We have the world’s best cybersecurity experts — we should use them to restore faith in elections.”

We tend to agree with our reader: we should clean up the process so long as there is concern — real or perceived. Of course, that’s easier said than done…

After highlighting Moderna’s COVID-19 vaccine, a reader says: “The only thing we can be sure of at this point is that COVID is less deadly for people under 50-years old, and far more deadly for those over 70.

“Given the virus is generally less serious for those who are young, we should be using selective measures to protect the old and vulnerable, not locking down schools and businesses. Moreover, we should be encouraging the old and vulnerable to get vaccinated.”

We’ve received plenty of feedback about a potential vaccine. Today, we take a look at some immediate problems that would need to be resolved ahead of widespread distribution of a vaccine…

Send your opinions to, TheRundownFeedback@SevenFigurePublishing.com.

Your Rundown for Friday, Nov. 20, 2020…

Vaccination Nation

The two pharmaceutical companies that appear to be pulling ahead in the race for a COVID-19 vaccine — Pfizer and Moderna — share a unique challenge.

The good news? The experimental vaccines from both companies have been found to be about 95% effective in protecting 72,000 clinical trial volunteers from contracting the novel coronavirus.

And both companies appear to have cracked the code on something scientists have been theorizing about for decades, using messenger RNA (mRNA) to solve some of the toughest medical mysteries.

“The concept: By making precise tweaks to synthetic mRNA and injecting people with it, any cell in the body could be transformed into an on-demand drug factory,” Stat News says.

So if the FDA grants emergency approval for Pfizer and Moderna’s vaccines, the technological implications can’t be overstated. We’re talking moon landing here…

“[Pfizer and Moderna] reiterated that they expect to produce up to 50 million doses this year and up to 1.3 billion doses in 2021,” CNBC reports.

But remember that unique challenge we mentioned earlier?

Both companies “said they are ‘confident’ in their ability to distribute the vaccine,” CNBC continues, but Pfizer’s “requires a storage temperature of minus 94 degrees Fahrenheit.

“By comparison, Moderna’s vaccine can be stored for up to six months at negative 4 degrees Fahrenheit.”

The need for cold storage poses a real-world problem for vaccine distribution, and in that case, Moderna seems to be leveling up.

However, we believe an American company might step in with a critical solution to save the day. More on that Monday…

Market Rundown for Friday, Nov. 20, 2020

S&P 500 futures are down 8 points to 3,574.

Oil’s steady at $41.63 for a barrel of WTI.

Gold’s added $14.60 to its price at $1,876.10 per ounce.

Bitcoin’s rallying — up 4.2% to $18,639.75.

Send your comments and questions to, TheRundownFeedback@SevenFigurePublishing.com.

Take care, readers, and we hope you enjoy the weekend.

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Break This Sacred Investing Rule to Profit From SPACs

According to data from Renaissance Capital, the average SPAC actually underperforms the average traditional IPO. That data is a little skewed because it primarily includes SPACs that did their deals before SPACs became mainstream and reputable this year. Still, the important takeaway is that you need to break a key investing rule if you want to be a successful SPAC investor…

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler